Introduction
============

Renal cell carcinoma (RCC) is the most common type of kidney cancer responsible for 90--95% of all cases, and accounting for \~3% of adult malignancies ([@b1-ol-0-0-8398]). Clear cell RCC (ccRCC) is the most aggressive RCC subtype and constitutes 70--80% of all RCC cases with the highest rates of local invasion, metastasis and mortality ([@b2-ol-0-0-8398]). RCC is usually asymptomatic in the early stages and, as the disease progresses, signs include hematuria, flank pain, abdominal masses and loin pain ([@b3-ol-0-0-8398]). An unhealthy lifestyle is a major cause of RCC, and it has been reported that smoking, obesity and hypertension have been estimated to cause \~50% of all cases ([@b4-ol-0-0-8398]). Additionally, hereditary factors have an impact on individual susceptibility to RCC ([@b5-ol-0-0-8398]). Other genetically-linked conditions also increase the risk of developing RCC, including hereditary papillary renal carcinoma, hereditary leiomyomatosis, hyperparathyroidism-jaw tumor syndrome, familial papillary thyroid carcinoma and sickle cell disease. The pathogenesis of RCC is extremely complex and is yet to be elucidated. Notably, an increasing number of biomarkers have been found to be involved in the pathogenesis of RCC. Matsuura *et al* ([@b6-ol-0-0-8398]) proved that the downregulation of *SAV1* and the consequent *YAP1* activation were involved in the pathogenesis of high-grade ccRCC. Furthermore, bioinformatics analyses demonstrated that microRNAs (miRNAs) were dysregulated in ccRCC and may contribute to kidney cancer pathogenesis by targeting more than 1 key molecule ([@b7-ol-0-0-8398]). A larger number of miRNAs are associated with key pathogenesis mechanisms of hypoxia and epithelial-to-mesenchymal transition, including *miR-200, miR-210, miR-155, miR-8a, miR-424, miR-381, miR-34a, miR-17-5p* and *miR-224* ([@b8-ol-0-0-8398]). In addition, promoter region methylation and transcriptional silencing are major mechanisms of tumor suppressor genes in RCC ([@b9-ol-0-0-8398]). Ricketts *et al* ([@b10-ol-0-0-8398]) reported that certain tumor suppressor genes were methylated in RCC tumor tissue (e.g., *SLC34A2* was specifically methylated in 63% of RCC cases, *OVOL1* in 40%, *DLEC1* in 20%, *TMPRSS2* in 26%, *SST* in 31% and *BMP4* in 35%). Therefore, the methylation analysis is an attractive strategy for investigating novel genes in the pathogenesis of RCC. In the present study article, an mRNA expression profile, a miRNA expression profile and a methylation profile of ccRCC were synthetically analyzed in order to screen potential pathogenic biomarkers via microarray analysis.

Materials and methods
=====================

### Microarray data

The microarray datasets of GSE96574, GSE71302 ([@b11-ol-0-0-8398]) and GSE61441 ([@b12-ol-0-0-8398]) were downloaded from the Gene Expression Omnibus (GEO) database ([www.ncbi.nlm.nih.gov/geo/](www.ncbi.nlm.nih.gov/geo/)). GSE96574, which was an mRNA expression profile with 5 ccRCC tissues and 5 normal kidney tissues, was detected with the platform of Agilent-067406 CBC lncRNA + mRNA microarray V4.0; GSE71302, an miRNA expression profile with 5 ccRCC tissues and 5 normal kidney tissues, was detected with the platform of Agilent-021827 Human miRNA Microarray V3; GSE61441, a methylation profile with 46 ccRCC tissues and 46 normal kidney tissues, was detected with the platform of Illumina HumanMethylation450 BeadChip.

### Data processing and differential analysis

For the profiles of GSE96574, GSE71302 and GSE61441, the raw data were obtained and normalized using the preprocess core function package V3.5 (<http://www.bioconductor.org/packages/release/bioc/html/preprocessCore.html>) ([@b13-ol-0-0-8398]). Subsequently, the differentially expressed genes (DEGs) and differentially expressed miRNAs (DEMs) were identified in ccRCC samples compared with normal kidney samples with the limma V3.18.13 software package (<http://www.bioconductor.org/packages/2.13/bioc/html/limma.html>). P\<0.05 and \|log~2~(fold-change)\|\>1 were used as threshold criteria. The two sample t-test and the β distribution test were used to identify the differentially methylated sites (DMSs), and DMSs were identified with P\<0.05 and \|Δβ\|\>0.2. Furthermore, the genes in which the DMSs were located were labeled using the annotation files of the methylation chip platform.

### Functional and pathway enrichment analysis of DEGs

Gene Ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses of DEGs were performed via the Database for Annotation, Visualization and Integrated Discovery (DAVID) V6.8 (<http://david.abcc.ncifcrf.gov/>) ([@b14-ol-0-0-8398]). GO terms and KEGG pathways were selected with P\<0.05.

### Target prediction of DEMs

To investigate the related regulation mechanisms of DEMs, the targets and their locations were predicted by the miRWalk V2.0 database (<http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk/>), which was a powerful and accurate database that displayed miRNAs, their corresponding target genes and binding sites in mice, rats and humans ([@b15-ol-0-0-8398]). Putative targets were predicted by \>5 bioinformatics algorithms among the 10 algorithms in the miRWalk database: DIANAmT V4.0 ([www.ma.uni-heidelberg.de/apps/zmf/mirwalk/diana-microt](www.ma.uni-heidelberg.de/apps/zmf/mirwalk/diana-microt)), miRanda -rel2010 ([www.ma.uni-heidelberg.de/apps/zmf/mirwalk/miranada](www.ma.uni-heidelberg.de/apps/zmf/mirwalk/miranada)), miRDB V4.0 ([www.ma.uni-heidelberg.de/apps/zmf/mirwalk/mirdb](www.ma.uni-heidelberg.de/apps/zmf/mirwalk/mirdb)), miRWalk V2.0 ([www.ma.uni-heidelberg.de/apps/zmf/mirwalk/mirwalk](www.ma.uni-heidelberg.de/apps/zmf/mirwalk/mirwalk)), RNAhybrid V2.1 ([www.ma.uni-heidelberg.de/apps/zmf/mirwalk/rnahybrid](www.ma.uni-heidelberg.de/apps/zmf/mirwalk/rnahybrid)), PICTAR4 ([www.ma.uni-heidelberg.de/apps/zmf/mirwalk/pictar4](www.ma.uni-heidelberg.de/apps/zmf/mirwalk/pictar4)), PICTAR5 ([www.ma.uni-heidelberg.de/apps/zmf/mirwalk/pictar5](www.ma.uni-heidelberg.de/apps/zmf/mirwalk/pictar5)), PITA ([www.ma.uni-heidelberg.de/apps/zmf/mirwalk/pipa](www.ma.uni-heidelberg.de/apps/zmf/mirwalk/pipa)), RNA22 V2 ([www.ma.uni-heidelberg.de/apps/zmf/mirwalk/rna22](www.ma.uni-heidelberg.de/apps/zmf/mirwalk/rna22)) and Targetscan V6.2 ([www.ma.uni-heidelberg.de/apps/zmf/mirwalk/targetscan](www.ma.uni-heidelberg.de/apps/zmf/mirwalk/targetscan)). Therefore, the miRNA-gene regulation pairs were screened out and the locations of the targets were drawn out.

### Combination analysis of DEGs, DEMs and DMSs

The corresponding genes of DMSs were identified based on the β-value. If multiple DMSs corresponded to a single gene, the average β-value of the DMSs was used as the β-value of the gene. The overlapped genes between the DEGs and the corresponding genes of DMSs were screened out with the threshold of \|Δβ\|\>0.2. The genes involved in the aforementioned miRNA-gene pairs and the DEGs were selected out and further analyzed with their corresponding DEMs and DMSs.

### Verification of associated genes and miRNAs in patients with ccRCC

A total of 10 patients with ccRCC, 32--57 years old (mean age, 63.2), were collected between February 2017 and March 2017, including 5 male patients and 5 female patients. The tumor tissues and adjacent non-cancerous tissues were collected with surgical resection. Written informed consent was obtained when the patients were accepted by the Second Hospital of Tianjin Medical University. All procedures were performed in accordance with the ethical standards of the institutional and/or national research committee. The total RNA was extracted using TRIzol (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA). Reverse transcription PCR (RT-PCR) and methylation-specific PCR (MS-PCR) were performed to detect the methylation status of *HAPLN1*. The mRNA levels of *HAPLN1, hsa-miR-204* and *hsa-miR-218* were tested by RT-PCR. RNA was reverse transcribed using the PrimeScript^®^ 1st Strand cDNA Synthesis kit (Takara Biotechnology Co., Ltd., Dalian, China) with the following temperature protocol: 30°C for 10 min, 42°C for 60 min and 95°C for 5 min. The SYBR^®^ Premix Ex Taq™ kit (Takara Biotechnology Co., Ltd.) and the Applied Biosystems™ QuantStudio™ 5 Real-Time PCR System (Applied Biosystems; Thermo Fisher Scientific, Inc.) were used to conduct PCR, according to the manufacturer\'s protocols. DNA methylation modification was performed using an EZ-DNA Methylation-Gold kit™ (Zymo Research Corp., Irvine, CA, USA), according to the manufacturer\'s protocols. All the primers were designed and synthesized by Takara Biotechnology Co., Ltd. The MSP primers of *HAPLN1* were as follows: Forward, 3′-AGGAGAATTTTTTTGGTGACGT-5′ and reverse, 3′-CTAAAAATCAAATAAAACTAACGCT-5′ (210 bp); and the RT-PCR primers were as follows: *HAPLN1* forward, 3′-TGGTGAGAAAGTGCCTCCTT-5′ and reverse, 3′-TAGCGCTCTTTCTCCTCACC-5′ (151 bp); *hsa-miR-204* forward, 3′-CAGTGCAGGGTCCGAGGTAT-5′ and reverse, 3′-GCTGGAAGGCAAAGGGACGT-5′ (180 bp); *hsa-miR-218* forward, 3′-CAGTGCAGGGTCCGAGGTAT-5′ and reverse, 3′-ATGGTTCCGTCAAGCACCATGG-5′ (205 bp); and β-actin forward, 5′-CTACAATGAGCTGCGTGTGG −3′ and reverse, 5′-AGGCATACAGGGACAACACA-3′ (308 bp). The thermocycling conditions were as follows: 95°C for 5 min; followed by 40 cycles of 95°C for 15 sec, 60°C for 30 sec, and 72°C for 35 sec; and a final 5 min at 72°C extension. The 2^−ΔΔCq^ method was used to calculate the relative expression value of the target gene ([@b16-ol-0-0-8398]).

### Statistical analysis

SPSS version 17.0 (SPSS Inc., Chicago, IL, USA) was used for all statistical analyses, and data are presented as the mean ± standard deviation. T test was used to compare the two groups and P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### DEGs, DEMs and DMSs

A total of 2,172 (1,089 upregulated and 1,083 downregulated) DEGs, 202 (91 upregulated and 111 downregulated) DEMs and 2,172 (1,305 upregulated and 867 downregulated) DMSs were identified in ccRCC samples compared with normal kidney samples. The top 20 most significantly upregulated/downregulated DEGs, DEMs and DMSs are presented in [Tables I](#tI-ol-0-0-8398){ref-type="table"}, [II](#tII-ol-0-0-8398){ref-type="table"} and [III](#tIII-ol-0-0-8398){ref-type="table"}, respectively. The location distribution of DMSs is presented in [Fig. 1](#f1-ol-0-0-8398){ref-type="fig"}, and they were primarily located in the gene coding region (31%) and the intergenic gene region (22%).

### Enriched GO terms and KEGG pathways

The DEGs were enriched in 1,015 GO terms and 69 KEGG pathways. The top 10 significantly enriched GO terms and KEGG pathways are presented in [Tables IV](#tIV-ol-0-0-8398){ref-type="table"} and [V](#tV-ol-0-0-8398){ref-type="table"}, respectively.

### Targets of DEMs

The target genes of DEMs were identified in at least 5 algorithms of the miRWalk database and therefore, 10,601 miRNA-gene pairs were obtained. The locations of the target genes and the regulation trends of the miRNA-gene pairs are presented in [Fig. 2](#f2-ol-0-0-8398){ref-type="fig"}. More targets were located in the 3′-UTR, fewer in the 5′-UTR and coding domain sequence (CDS) and the majority of miRNA-gene pairs were negatively regulated.

### Combination of DEGs, DEMs and DMSs

In total, 143 DEGs involved in DMSs were identified in ccRCC samples compared with normal kidney samples. The gene expression level and DNA methylation level of 45 of these genes exhibited inverse associations ([Fig. 3](#f3-ol-0-0-8398){ref-type="fig"}). A total of 851 miRNA-gene pairs were simultaneously involved in DEGs, DEMs and DMS-located genes. Among them, there were 127 miRNA-gene pairs, the genes of which were negatively associated with corresponding DEMs and DMSs. Furthermore, 32 of these miRNA-gene pairs, of which the targeted genes had well-defined genetic locations, are presented in [Table VI](#tVI-ol-0-0-8398){ref-type="table"}. The 32 miRNA-gene pairs were composed of 15 genes and 14 miRNAs. *HAPLN1* had the most significant differences in expression and was regulated by *hsa-miR-204* and *hsa-miR-218*. Results of the verification are presented in [Table VII](#tVII-ol-0-0-8398){ref-type="table"}; *HAPLN1* had a lower expression level and a significantly higher methylation level in ccRCC tissues than in adjacent non-cancerous tissues (P\<0.0001); the expression of *hsa-miR-204* and *hsa-miR-218* was significantly higher in ccRCC tissues than in adjacent non-cancerous tissues (P\<0.0001).

Discussion
==========

Genetic variations are associated with the occurrence and development of RCC. miRNAs regulate gene expression and serve an important role in the development of cancer. The methylation status of certain genes is associated with cancer development and metastatic recurrence in ccRCC. In the present study, the mRNA and miRNA expression profiles, as well as the methylation profiles, were analyzed. A total of 2,172 DEGs, 202 DEMs and 2,172 DMSs were identified in ccRCC samples compared with normal kidney samples. The DEGs were enriched in 1,015 GO terms, and the majority of them were associated with the plasma membrane, extracellular exosome and material transport, including the plasma membrane part, extracellular exosome and ion transport ([Table IV](#tIV-ol-0-0-8398){ref-type="table"}). Plasma membrane part was the most significant GO term for the DEGs. Plasma membrane part is a cellular component term, which participates in regulating DNA methylation and the mechanism of glioma ([@b17-ol-0-0-8398]--[@b19-ol-0-0-8398]). Human plasma membrane-associated sialidase (NEU3), an important cellular component of cell membrane part, serves crucial roles in the regulation of cell surface functions. Ueno *et al* ([@b20-ol-0-0-8398]) reported that NEU3 was upregulated in RCC and promoted interleukin-6-induced apoptosis suppression and cell motility. Tringali *et al* ([@b21-ol-0-0-8398]) demonstrated a crucial role of NEU3 in RCC malignancy by acting as a key regulator of the β1 integrin-recycling pathway and FAK/Akt signaling. Therefore, the cellular component term of plasma membrane part was associated with the progression of RCC. Furthermore, the DEGs were enriched in 69 KEGG pathways, including graft-versus-host disease, staphylococcus aureus infection, type I diabetes mellitus and rheumatoid arthritis. Graft-versus-host disease (GvHD) was the most significant pathway. GvHD is a medical complication following the receipt of transplanted tissue from a genetically different person. It is commonly associated with stem cell transplant (bone marrow transplant), but the term also applies to other forms of tissue graft. A previous study revealed a reduced rate of GvHD during cyclophosphamide-using non-myeloablative cell therapy against renal cancer ([@b22-ol-0-0-8398]). Another study indicated that the graft vs. tumor reactivity following allogeneic stem cell transplantation may be unavoidably associated with GvHD in patients with RCC ([@b23-ol-0-0-8398]). Additionally, Massenkeil *et al* ([@b24-ol-0-0-8398]) reported that non-myeloablative stem cell transplantation in metastatic renal cell carcinoma delayed GvHD. In the present study, we hypothesized that GvHD may serve certain roles in the pathogenesis of RCC and that further functional studies were required.

Following combination analysis of DEGs, DEMs and DMSs, *HAPLN1* was one of the DEGs that was negatively regulated by their corresponding targeted DEMs and DMSs, and it had well-defined genetic locations. Furthermore, *HAPLN1* exhibited the most pronounced differences in expression, and was negatively regulated by *hsa-miR-204* and *hsa-miR-218*. [Table VI](#tVI-ol-0-0-8398){ref-type="table"} indicates that *hsa-miR-204* and *hsa-miR-218* targeted the 3′-UTR of *HAPLN1*. It is well known that miRNAs block the transcription of their target genes when they target the 3′-UTR ([@b25-ol-0-0-8398]). In the present study, the expression of *HAPLN1* was negatively associated with the expression of *hsa-miR-204* and *hsa-miR-218*. Additionally, the methylation site of *HAPLN1* is located in the transcriptional start site 1,500 bp (TSS1500) region. In this region, gene methylation may lead to deletion or downregulation of gene expression. In the present study, the expression of *HAPLN1* was negatively associated with the methylation level. Furthermore, *HAPLN1* and *hsa-miR-204* were the most significantly different gene and DEM, respectively ([Table VI](#tVI-ol-0-0-8398){ref-type="table"}). *HAPLN1* is a protein that in humans is encoded by the *HAPLN1* gene. *HAPLN1* is an extracellular matrix component serving an important role in heart development, and is associated with cerebral creatine deficiency syndrome and fracture. It was reported that overexpression of HAPLN1 and its SP-IgV domain increased the tumorigenic properties of mesothelioma ([@b26-ol-0-0-8398]). Yau *et al* ([@b27-ol-0-0-8398]) identified *HAPLN1* as a novel prognostic gene candidate to predict the outcome of breast cancer. Mebarki *et al* ([@b28-ol-0-0-8398]) proved that HAPLN1 reflected a signaling network leading to stemness, mesenchymal commitment and progression in hepatocellular carcinoma. The present study, revealed that *HAPLN1* had a low expression level and a high methylation level in ccRCC tissues ([Table VII](#tVII-ol-0-0-8398){ref-type="table"}), which may be involved in the occurrence of ccRCC. *Hsa-miR-204* was identified to be highly expressed in lymphocytic leukemia, and it was differentially expressed during the progression of recurrence in hepatocellular carcinoma and gastric cancer ([@b29-ol-0-0-8398]--[@b31-ol-0-0-8398]). *Hsa-miR-218* was reported to serve an important role in the proliferation and metastasis of colon carcinoma ([@b32-ol-0-0-8398]). Additionally, *hsa-miR-218* may inhibit the multidrug resistance of gastric cancer cells ([@b33-ol-0-0-8398]). In the present study, h*sa-miR-204* and *hsa-miR-218* were proven to be highly expressed in ccRCC tissues, and may serve certain roles in the pathogenesis of RCC by targeting *HAPLN1*.

In conclusion, the present study identified certain biomarkers of RCC by combination analysis of a mRNA expression profile, a miRNA expression profile and a methylation profile, including *HAPLN1, hsa-miR-204* and *hsa-miR-218*. Additionally, the cellular component of plasma membrane part and the pathway of GvHD may be involved in the pathogenesis of RCC. However, there are certain limitations to the present study. The sample size was small in the profiles and verification, and therefore the identified genes and miRNAs may have greater specificity and less universality. The biomarkers screened in the present study provided an indication to study the pathogenesis of RCC. Additionally, *HAPLN1, hsa-miR-204* and *hsa-miR-218* require further investigation in larger samples to elucidate their exact function and clinical significance.
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###### 

The top 20 most significant differentially expressed genes in clear cell renal cell carcinoma samples compared with normal kidney samples.

  Gene       Log FC   Mean expression   t         P-value       \|∆β\|
  ---------- -------- ----------------- --------- ------------- --------
  NDUFA4L2   −4.013   7.400             −20.749   1.81×10^−6^   13.385
  HK2        −3.156   4.706             −20.558   1.81×10^−6^   13.307
  PCSK6      −3.022   6.983             −21.826   1.81×10^−6^   13.800
  TMEM213    5.025    4.467             19.505    2.57×10^−6^   12.862
  NPHS2      4.386    5.637             18.708    3.36×10^−6^   12.500
  DMRT2      3.306    3.416             18.248    3.77×10^−6^   12.282
  BHLHE41    −3.750   5.475             −16.519   8.56×10^−6^   11.385
  SLC47A2    4.148    5.832             16.690    8.56×10^−6^   11.479
  SFRP1      2.895    5.473             16.042    1.05×10^−5^   11.115
  AQP6       2.851    4.375             15.661    1.24×10^−5^   10.892
  ENO2       −3.218   5.839             −15.328   1.24×10^−5^   10.690
  CNTN1      2.911    4.580             15.444    1.24×10^−5^   10.762
  ATP6V0A4   3.492    4.469             15.137    1.24×10^−5^   10.573
  TMEM52B    4.297    7.647             15.116    1.24×10^−5^   10.560
  CLCNKB     4.451    5.645             15.133    1.24×10^−5^   10.570
  PAH        6.079    5.914             14.721    1.55×10^−5^   10.310
  NPHS1      2.549    4.357             14.582    1.57×10^−5^   10.220
  ATP6V0D2   4.435    5.594             14.548    1.57×10^−5^   10.198
  ERBB4      3.221    3.994             14.425    1.64×10^−5^   10.117
  MT1G       5.561    7.111             14.195    1.85×10^−5^   9.964

###### 

The top 20 most significant differentially expressed microRNA in clear cell renal cell carcinoma samples compared with normal kidney samples.

  Gene              Log FC       Mean expression   t        P-value       \|∆β\|
  ----------------- ------------ ----------------- -------- ------------- --------
  hsa-miR-200c      353.683      221.596           17.981   1.27×10^−5^   6.195
  hsa-miR-141       352.019      220.817           12.544   1.27×10-5     4.868
  hur_6             23789.981    42317.538         10.142   0.001         3.852
  hsa-miR-342-5p    −19.321      60.751            −9.957   0.001         3.757
  hsa-miR-21        −36961.351   38145.395         −9.888   0.001         3.720
  hsa-miR-25        −278.196     487.476           −7.556   0.008         2.223
  hsa-miR-34a       −2270.488    1752.008          −7.214   0.009         1.951
  hsa-miR-15a       −1651.827    2258.899          −7.019   0.010         1.789
  hsa-miR-138       34.895       59.818            6.732    0.012         1.541
  hsa-miR-200b      1449.075     1441.078          6.511    0.014         1.341
  hsa-miR-136       11.585       55.781            6.207    0.016         1.055
  hsa-miR-124       18.996       54.063            6.162    0.016         1.011
  hsa-miR-34a       −36.297      64.852            −6.140   0.016         0.990
  hsa-miR-532-5p    153.632      191.707           6.050    0.016         0.901
  hsa-miR-342-3p    −357.194     500.970           −5.958   0.016         0.809
  hsa-miR-28-3p     −5.341       48.193            −5.938   0.016         0.789
  hsa-miR-30a       8011.852     8679.002          5.902    0.016         0.752
  hsa-miR-193a-5p   −24.702      73.083            −5.799   0.016         0.647
  hsa-miR-362-3p    120.012      182.590           5.745    0.016         0.591
  hsa-miR-629       −4.148       46.205            −5.698   0.016         0.542

###### 

The top 20 most significant differentially methylated sites in clear cell renal cell carcinoma samples compared with normal kidney samples.

  ID_REF       ∆β       P-value        Gene      Location
  ------------ -------- -------------- --------- -----------------
  cg13008315   −0.293   5.53×10^−44^             IGS
  cg22164891   −0.473   1.30×10^−41^   ZNF217    TSS200
  cg00246451   −0.400   2.34×10^−41^   ARHGEF2   TSS1500
  cg07166409   −0.315   1.75×10^−40^   SEMA4C    5′UTR
  cg00026222   −0.308   8.4×10^−40^              IGS
  cg19756430   −0.273   8.85×10^−39^             IGS
  cg09228833   −0.489   1.44×10^−38^   ZNF217    TSS200
  cg19643921   −0.257   5.50×10^−37^   NUMBL     TSS1500
  cg01287592   −0.214   6.71×10^−37^   DENND3    5′UTR
  cg04312358   −0.259   1.08×10^−36^   NUMBL     TSS1500
  cg09029902   −0.480   1.09×10^−36^   ZNF217    5′-UTR; 1stExon
  cg20979153   −0.372   1.21×10^−36^   ZNF217    TSS200
  cg08909806   −0.245   1.22×10^−36^   TSPO      5′UTR
  cg27107144   −0.211   2.19×10^−36^   AES       Body
  cg07797853   −0.203   1.54×10^−35^             IGS
  cg13266096   −0.328   2.05×10^−35^   MTA2      Body
  cg11588197   −0.384   3.17×10^−35^   ETS1      Body
  cg27638217   −0.312   4.23×10^−35^             IGS
  cg08995609   −0.374   1.19×10^−34^   RIN1      TSS200
  cg06349174   −0.211   1.58×10^−34^   STIM1     1stExon; 5′UTR

###### 

The top 10 significantly enriched GO terms of differentially expressed genes.

  Category      Term                                                 Count   P-value
  ------------- ---------------------------------------------------- ------- --------------
  GOTERM_CC_5   GO:0044459\~plasma membrane part                     504     6.33×10^−41^
  GOTERM_CC_5   GO:0070062\~extracellular exosome                    510     6.68×10^−35^
  GOTERM_CC_5   GO:0031226\~intrinsic component of plasma membrane   335     3.50×10^−28^
  GOTERM_CC_5   GO:0005887\~integral component of plasma membrane    325     5.01×10^−28^
  GOTERM_BP_5   GO:0006811\~ion transport                            280     3.33×10^−23^
  GOTERM_BP_5   GO:0043436\~oxoacid metabolic process                185     2.49×10^−22^
  GOTERM_BP_5   GO:0019752\~carboxylic acid metabolic process        184     3.05×10^−22^
  GOTERM_CC_5   GO:0009897\~external side of plasma membrane         81      9.78×10^−20^
  GOTERM_CC_5   GO:0016324\~apical plasma membrane                   89      4.76×10^−19^
  GOTERM_CC_5   GO:0098590\~plasma membrane region                   194     1.48×10^−18^

GO, gene ontology.

###### 

The top 10 significantly enriched KEGG pathways of differentially expressed genes.

  Category       Term                                       Count   P-value
  -------------- ------------------------------------------ ------- --------------
  KEGG_PATHWAY   hsa05332:Graft-versus-host disease         21      2.23×10^−10^
  KEGG_PATHWAY   hsa05150:Staphylococcus aureus infection   27      4.61×10^−10^
  KEGG_PATHWAY   hsa04940:Type I diabetes mellitus          22      9.44×10^−9^
  KEGG_PATHWAY   hsa05323:Rheumatoid arthritis              33      2.66×10^−8^
  KEGG_PATHWAY   hsa04145:Phagosome                         47      2.72×10^−8^
  KEGG_PATHWAY   hsa05330:Allograft rejection               20      2.76×10^−8^
  KEGG_PATHWAY   hsa05322:Systemic lupus erythematosus      41      2.74×10^−7^
  KEGG_PATHWAY   hsa04978:Mineral absorption                21      3.97×10^−7^
  KEGG_PATHWAY   hsa03320:PPAR signaling pathway            26      5.06×10^−7^
  KEGG_PATHWAY   hsa04514:Cell adhesion molecules (CAMs)    42      5.25×10^−7^

KEGG, Kyoto Encyclopedia of Genes and Genomes.

###### 

The 32 microRNA-gene pairs, the target genes of which were negatively regulated by corresponding differentially expressed miRNA and differentially methylated sites, and had well-defined genetic locations.

  MicroRNA          Gene       MiRNA_logFC   Gene_LogFC   Beta_diff   Gene_locus   Methy_loc
  ----------------- ---------- ------------- ------------ ----------- ------------ ----------------
  hsa-miR-204       HAPLN1     3179.242      −2.756       0.202       3′-UTR       TSS1500
  hsa-miR-218       HAPLN1     189.092       −2.756       0.202       3′-UTR       TSS1500
  hsa-miR-106b      SLC26A4    −519.831      2.631        −0.227      3′-UTR       TSS1500; Body
  hsa-miR-106b      BPHL       −519.831      1.878        −0.211      3′-UTR       Body
  hsa-miR-124       DLX5       18.996        −1.652       0.221       3′-UTR       Body
  hsa-miR-125a-5p   ALOX5      125.869       −1.537       0.288       3′-UTR       Body
  hsa-miR-183       ALOX5      10.550        −1.537       0.288       3′-UTR       Body
  hsa-miR-125a-5p   LEP        125.869       −1.314       0.236       3′-UTR       TSS1500
  hsa-miR-29b       LEP        1101.186      −1.314       0.236       3′-UTR       TSS1500
  hsa-miR-29c       LEP        1699.774      −1.314       0.236       3′-UTR       TSS1500
  hsa-miR-30b       LEP        1746.324      −1.314       0.236       3′-UTR       TSS1500
  hsa-let-7a        PLCB2      4972.969      −1.303       0.206       3′-UTR       Body
  hsa-let-7c        PLCB2      580.187       −1.303       0.206       3′-UTR       Body
  hsa-let-7f        PLCB2      4506.520      −1.303       0.206       3′-UTR       Body
  hsa-let-7g        PLCB2      531.008       −1.303       0.206       3′-UTR       Body
  hsa-miR-204       PDE4B      3179.242      −1.224       0.232       3′-UTR       TSS200;TSS1500
  hsa-miR-125a-5p   PIK3R5     125.869       −1.203       0.222       3′-UTR       TSS200
  hsa-miR-29b       PIK3R5     1101.186      −1.203       0.222       3′-UTR       TSS200
  hsa-miR-29c       PIK3R5     1699.774      −1.203       0.222       3′-UTR       TSS200
  hsa-miR-337-5p    FOXA2      6.426         −1.198       0.233       3′-UTR       Body; 3′UTR
  hsa-let-7a        HLX        3179.242      −2.756       0.202       3′-UTR       3′-UTR
  hsa-let-7c        HLX        189.092       −2.756       0.202       3′-UTR       3′-UTR
  hsa-let-7f        HLX        −519.831      2.631        −0.227      3′-UTR       3′-UTR
  hsa-let-7g        HLX        −519.831      1.878        −0.211      3′-UTR       3′-UTR
  hsa-miR-30b       HLX        1746.324      −1.157       0.206       3′-UTR       3′-UTR
  hsa-miR-125a-5p   ONECUT2    125.869       −1.087       0.271       CDS          1stExon
  hsa-miR-124       HLA-DPB1   18.996        −1.084       0.220       3′-UTR       Body
  hsa-miR-106b      ADAMTSL2   −519.831      1.073        −0.277      3′-UTR       Body
  hsa-let-7a        MYO1F      4972.969      −1.050       0.212       CDS          Body
  hsa-let-7c        MYO1F      580.187       −1.050       0.212       CDS          Body
  hsa-let-7f        MYO1F      4506.520      −1.050       0.212       CDS          Body

###### 

Results of methylation-specific polymerase chain reaction and reverse transcription-polymerase chain reaction.

  Group              HAPLN1-methy   HAPLN1-mRNA   Hsa-miR-204   Hsa-miR-218
  ------------------ -------------- ------------- ------------- -------------
  ccRCC tissues      4.228±1.061    0.466±0.512   4.377±1.057   4.627±1.189
  Adjacent tissues   1.034±0.024    1.064±0.671   1.037±0.021   1.029±0.020
  P-value            \<0.0001       \<0.0001      \<0.0001      \<0.0001
  T                  9.69           −6.06         15.23         14.93

n=10. ccRCC, clear cell renal cell carcinoma.
